MX2022004736A - Derivados de acido 3-(4-(11h-dibenzo [b, e] [1, 4] azepin-6-il)piperazin-1-il)- y 3-(4- dibenzo [b, f] [1, 4] oxazepin/tiazepin/diazepin-11-il)piperazin-1-il)propanoico como moduladores de los receptores h1 y 5-ht2a para el tratamiento de los trastornos del sue?o. - Google Patents

Derivados de acido 3-(4-(11h-dibenzo [b, e] [1, 4] azepin-6-il)piperazin-1-il)- y 3-(4- dibenzo [b, f] [1, 4] oxazepin/tiazepin/diazepin-11-il)piperazin-1-il)propanoico como moduladores de los receptores h1 y 5-ht2a para el tratamiento de los trastornos del sue?o.

Info

Publication number
MX2022004736A
MX2022004736A MX2022004736A MX2022004736A MX2022004736A MX 2022004736 A MX2022004736 A MX 2022004736A MX 2022004736 A MX2022004736 A MX 2022004736A MX 2022004736 A MX2022004736 A MX 2022004736A MX 2022004736 A MX2022004736 A MX 2022004736A
Authority
MX
Mexico
Prior art keywords
dibenzo
piperazin
oxazepin
treatment
thiazepin
Prior art date
Application number
MX2022004736A
Other languages
English (en)
Inventor
Mark E Duggan
Dale M Edgar
Original Assignee
Alairion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alairion Inc filed Critical Alairion Inc
Publication of MX2022004736A publication Critical patent/MX2022004736A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/18—[b, e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación se refiere a los derivados de ácido 3-(4-(11H-dibenzo [b, e] [1, 4] azepin-6-il)piperazin-1-il)-, 3-(4-dibenzo [b, f] [1, 4] oxazepin-11-il)piperazin-1-il)-, 3-(4-dibenzo [b, f] [1, 4] tiazepin-11-il)piperazin-1-il)- y 3-(4-dibenzo [b, f] [1, 4] diazepin-11-il)piperazin-1-il)-propanoi co de las fórmulas (I), (II) y (II'): en donde X es CR7R8, O, S o NR7, y a sus sales farmacéuticamente aceptables, composiciones farmacéuticas, métodos para su preparación, así como a los compuestos para usarse en los métodos de tratamiento médico. Los compuestos que se dan a conocer en el presente documento son útiles para la modulación de los receptores H1 y 5-HT2A, y se van a utilizar en el tratamiento de los trastornos del sueño tales como la fragmentación del sueño, el sueño/despertar perturbado, y el umbral de excitación. La presente descripción da a conocer la síntesis y caracterización de los compuestos de ejemplo, así como los datos farmacológicos de los mismos (por ejemplo, páginas 143 a 224; ejemplos 1 a 33; compuestos 1 a 39; tablas A a R). Un compuesto de ejemplo es, por ejemplo, el ácido 3-(4-(7-cloro-3-metildibenzo [b, f] [1, 4] oxazepin-11-il)piperazi n-1-il)-2, 2-dimetil propanoico (ejemplo 1, compuesto 1): (ver Fórmula).
MX2022004736A 2019-10-21 2020-10-20 Derivados de acido 3-(4-(11h-dibenzo [b, e] [1, 4] azepin-6-il)piperazin-1-il)- y 3-(4- dibenzo [b, f] [1, 4] oxazepin/tiazepin/diazepin-11-il)piperazin-1-il)propanoico como moduladores de los receptores h1 y 5-ht2a para el tratamiento de los trastornos del sue?o. MX2022004736A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962923762P 2019-10-21 2019-10-21
US202063002096P 2020-03-30 2020-03-30
PCT/US2020/056520 WO2021080997A1 (en) 2019-10-21 2020-10-20 3-(4-(11h-dibenzo[b,e][1,4]azepin-6-yl)piperazin-1-yl)- and 3-(4-(dibenzo[b,f][1,4]oxazepin/thiazepin/diazepin-11-yl)piperazin-1-yl)-propano ic acid derivatives as h1 and 5-ht2a-receptor modulators for the treatment of sleep disorders

Publications (1)

Publication Number Publication Date
MX2022004736A true MX2022004736A (es) 2022-07-27

Family

ID=73543319

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004736A MX2022004736A (es) 2019-10-21 2020-10-20 Derivados de acido 3-(4-(11h-dibenzo [b, e] [1, 4] azepin-6-il)piperazin-1-il)- y 3-(4- dibenzo [b, f] [1, 4] oxazepin/tiazepin/diazepin-11-il)piperazin-1-il)propanoico como moduladores de los receptores h1 y 5-ht2a para el tratamiento de los trastornos del sue?o.

Country Status (11)

Country Link
US (1) US11046651B2 (es)
EP (1) EP4048667A1 (es)
JP (1) JP2023501000A (es)
KR (1) KR20220084369A (es)
CN (1) CN114929688A (es)
AU (1) AU2020370063A1 (es)
BR (1) BR112022007503A2 (es)
CA (1) CA3154630A1 (es)
IL (1) IL292370A (es)
MX (1) MX2022004736A (es)
WO (1) WO2021080997A1 (es)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH03184963A (ja) 1989-12-13 1991-08-12 Hokuriku Seiyaku Co Ltd ジベンズオキサゼピン誘導体
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
JPH05163245A (ja) 1991-12-13 1993-06-29 Hokuriku Seiyaku Co Ltd ジベンズアゼピン誘導体
JPH05345765A (ja) * 1992-04-16 1993-12-27 Hokuriku Seiyaku Co Ltd ジベンズアゼピン誘導体
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
CA2463579A1 (en) 2001-10-16 2003-04-24 Hypnion, Inc. Treatment of cns disorders using cns target modulators
CN1681388A (zh) 2002-09-18 2005-10-12 Fmc有限公司 三环衍生物杀虫剂
WO2004056182A1 (en) 2002-12-20 2004-07-08 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
US7550454B2 (en) 2003-12-22 2009-06-23 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2008021463A2 (en) 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
JP4533391B2 (ja) * 2004-01-16 2010-09-01 エフ．ホフマン−ラ ロシュ アーゲー 中枢神経系疾患の処置のための５−ヒドロキシトリプタミンレセプター（５−ｈｔ）のモジュレーターとしての、１−ベンジル−５−ピペラジン−１−イル−３，４−ジヒドロ−１ｈ−キナゾリン−２−オン誘導体、ならびにそれぞれの１ｈ−ベンゾ（１，２，６）チアジアジン−２，２−ジオキシドおよび１，４−ジヒドロベンゾ（ｄ）（１，３）オキサジン−２−オン誘導体
JP5049129B2 (ja) 2004-09-21 2012-10-17 ハイプニオン・インコーポレイテッド ロキサピン類縁体およびそれらの使用方法
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
US7563785B2 (en) * 2004-10-29 2009-07-21 Hypnion, Inc. Quetiapine analogs and methods of use thereof
TW200640467A (en) 2005-02-14 2006-12-01 Combinatorx Inc Compounds and uses thereof
US20060252744A1 (en) 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
EP1937614A1 (en) 2005-10-17 2008-07-02 Arcadia Pharmaceuticals Inc. Iron catalyzed cross-coupling reactions of imidoyl derivatives
US20080090805A1 (en) 2005-10-17 2008-04-17 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
WO2007047737A1 (en) 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
US20070105836A1 (en) 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
CA2704836C (en) 2007-11-28 2015-12-29 Nektar Therapeutics Oligomer-tricyclic conjugates
US20120129834A1 (en) * 2010-09-17 2012-05-24 Buck Institute For Research On Aging Serotonin receptor antagonists for use in the treatment of huntington's disease
WO2014116684A1 (en) 2013-01-22 2014-07-31 Edward Roberts Non-peptidic neuropeptide y receptor modulators
EP3449918A1 (en) 2017-09-01 2019-03-06 Technische Universität Dortmund Bmp-mimetics
WO2019245047A1 (ja) 2018-06-21 2019-12-26 国立研究開発法人量子科学技術研究開発機構 人工受容体に結合する新規化合物、人工受容体のイメージング方法、アゴニストまたはアンタゴニスト、治療薬、コンパニオン診断薬、神経細胞のイメージング方法

Also Published As

Publication number Publication date
WO2021080997A1 (en) 2021-04-29
JP2023501000A (ja) 2023-01-17
US20210114989A1 (en) 2021-04-22
CN114929688A (zh) 2022-08-19
KR20220084369A (ko) 2022-06-21
BR112022007503A2 (pt) 2022-07-12
US11046651B2 (en) 2021-06-29
CA3154630A1 (en) 2021-04-29
IL292370A (en) 2022-06-01
AU2020370063A1 (en) 2022-06-02
EP4048667A1 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
JP5186219B2 (ja) 置換アリールアミン化合物および５−ｈｔ６調節因子としてのその使用
SE0202462D0 (sv) Novel use
NO20075641L (no) Kroman og kromenderivater og ders anvendelse
MY132565A (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
MX2009012371A (es) Metabolitos de derivados de (tio)-carbamoil-ciclohexano.
GEP20135730B (en) Trans-4-{2-[4-(2,3-dichlorophe-nyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treatment of schizophrenia
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
KR950700258A (ko) 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체(heterocyclic carbonic acid derivatives which bind to retinoid receptors(rar))
TW200531694A (en) Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
GEP20135731B (en) Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethyl carbamoyl-cyclohexylamine for acute mania treatment
AR118278A2 (es) Compuestos derivados de piperazinil-alquil-4(3h)-quinazolinonas
BR9812238A (pt) Composto, uso deste, processo para a preparação do mesmo, formulação farmacêutica, e, processos para o tratamento de distúrbios do sistema nervoso central e/ou incontinência urinária, ou vasoespasmo, ou para controle de crescimento de tumores, e para o tratamento de distúrbios mediados por 5-hidroxitriptamina
MX2022015886A (es) Derivados de amidopirimidona.
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
RU2005122615A (ru) Соединения n-(индолэтил)циклоамина
MXPA01007940A (es) Derivados de azabicicloalcano y usos terapeuticos de los mismos.
WO2007099302A3 (en) Methods of maintaining oral health in animals using morpholine derivatives
MX2022004736A (es) Derivados de acido 3-(4-(11h-dibenzo [b, e] [1, 4] azepin-6-il)piperazin-1-il)- y 3-(4- dibenzo [b, f] [1, 4] oxazepin/tiazepin/diazepin-11-il)piperazin-1-il)propanoico como moduladores de los receptores h1 y 5-ht2a para el tratamiento de los trastornos del sue?o.
Linder et al. (2R, 3S)-(+)-and (2S, 3R)-(−)-Halofuginone lactate: Synthesis, absolute configuration, and activity against Cryptosporidium parvum
HUP0402515A2 (hu) Szubsztituált új N-[4-(1H-imidazol-1-il)-2-fluor-fenil]-3-(trifluor-metil)-1H-pirazol-5-karboxamidok Xa faktor inhibitorok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
SE9900190D0 (sv) New compounds
ES2021940A6 (es) Procedimiento para la preparacion de nuevos derivados de pirimidina con actividad serotoninergica.
JP5719985B2 (ja) ジフェニルメチルピペラジン誘導体
CR20230331A (es) Derivados de pirazolamida